abstract |
Bispecifics made from antibody fragments are subject to biophysical and pharmacokinetic barriers, while the drawback of being constructed in a full-length antibody-like format is that they are in the absence of primary target antigen. The present invention provides a novel bispecific antibody that solves these problems, since it causes nonspecific activation and potentially toxicity by polyvalently associating with a co-target antigen. A novel bispecific antibody specific for CD3 and CD38 comprising: a) a CD3 binding domain, b) a monovalent CD123 binding domain, and c) a first Fc domain and a second Fc. A heterodimeric antibody comprising a domain. [Selection diagram] None |